Farallon Capital Group Acquires 5.1% Stake in InflaRx N.V.

On May 14, 2026, Farallon Capital Management and its associated entities filed a Schedule 13G reporting a new collective beneficial ownership position in InflaRx N.V. (IFRX). The reporting group, which includes various Farallon Funds and individual managing members, reported an aggregate ownership of 7,500,000 ordinary shares, representing approximately 5.1% of the company. Individual funds within the group hold varying portions of these shares, with Farallon Capital Offshore Investors II, L.P. holding the largest single fund stake at 3,380,250 shares (2.3%). The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing control of the issuer. Key individual reporting persons include Joshua J. Dapice, Philip D. Dreyfuss, and Hannah E. Dunn, among others, all of whom may be deemed to share voting and dispositive power over the reported securities. This filing marks a significant new institutional position for the Farallon group in the German-based biopharmaceutical company.